SCHEMBL5223653

SCHEMBL5223653

C[C@H](c1cccc2ccccc12)N1[CH]CN(C[C@@H](O)COc2ccc3oc(-c4ccccc4)nc3c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.40
USP2 O75604 2/20 0.39
MAPT P10636 2/20 0.39
MAPK1 P28482 2/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
TLR9 Q9NR96 1/20 0.38
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6206447 0.88 SMN1; SMN2 (0.43) MAPTLMNACYP1A2CYP3A4CYP2C9
SCHEMBL5227545 0.88 SMN1; SMN2 (0.43) MAPTLMNACYP1A2CYP3A4CYP2C9
SCHEMBL4032410 0.83 CYP3A4 (0.51) CYP1A2CYP3A4CYP2C9
SCHEMBL4032517 0.83 CYP3A4 (0.51) CYP1A2CYP3A4CYP2C9
SCHEMBL5224695 0.81 CYP3A4 (0.54) CYP1A2CYP3A4CYP2C9
SCHEMBL5228451 0.77 PRMT5 (0.41) USP2CYP1A2CYP3A4CYP2C9KDM4E
SCHEMBL5224914 0.77 PRMT5 (0.41) USP2CYP1A2CYP3A4CYP2C9KDM4E
SCHEMBL5901370 0.76 PKM (0.49) MAPK1SMN1; SMN2KDM4EALDH1A1TLR9
SCHEMBL5965265 0.76 PKM (0.49) MAPK1SMN1; SMN2KDM4EALDH1A1TLR9
SCHEMBL4040185 0.76 PKM (0.49) MAPK1SMN1; SMN2KDM4EALDH1A1TLR9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed